Press release - 22/05/2024 Stretched beyond the limits of the cell: the molecular biomechanics of collagen Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stretched-beyond-limits-cell-molecular-biomechanics-collagen
Funding 4C Accelerator Tübingen Funding programme, Funded by: Medical Innovations Incubator GmbH, Ministerium für Wirtschaft, Arbeit und Tourismus BW, Startup BW & B. Braun-Stiftung, sb_search.searchresult.label.programSubmissionDate: 22/07/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/4c-accelerator-tuebingen
Funding 4C Accelerator Tübingen Funding programme, Funded by: Medical Innovations Incubator GmbH, Ministerium für Wirtschaft, Arbeit und Tourismus BW, Startup BW & B. Braun-Stiftung, sb_search.searchresult.label.programSubmissionDate: 22/07/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/4c-accelerator-tuebingen
Funding 4C Accelerator Tübingen Funding programme, Funded by: Medical Innovations Incubator GmbH, Ministerium für Wirtschaft, Arbeit und Tourismus BW, Startup BW & B. Braun-Stiftung, sb_search.searchresult.label.programSubmissionDate: 22/07/2024 https://www.bio-pro.de/en/service/funding/4c-accelerator-tuebingen
Funding EIC Transition Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 18/09/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/eic-transition-1
Funding EIC Transition Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 18/09/2024 https://www.bio-pro.de/en/service/funding/eic-transition-2024
Funding EIC Transition Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 18/09/2024 https://www.biooekonomie-bw.de/en/databases/funding/eic-transition-1
Funding EIC Accelerator Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 03/10/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/eic-accelerator
Funding EIC Accelerator Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 03/10/2024 https://www.bio-pro.de/en/service/funding/eic-accelerator
Funding EIC Pathfinder Challenges Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 16/10/2024 https://www.gesundheitsindustrie-bw.de/en/database/funding/eic-pathfinder-challenges
Funding EIC Pathfinder Challenges Funding programme, Funded by: European Commission, sb_search.searchresult.label.programSubmissionDate: 16/10/2024 https://www.bio-pro.de/en/service/funding/eic-pathfinder-challenges
Press release - 20/05/2024 seleon GmbH becomes part of the aesco solutions group On May 17, 2024, aesco solutions, a leading group for production and development services (CDMO) for medical device companies, and D11Z. Ventures GmbH & Co. KG (formerly Zukunftsfonds Heilbronn) announce the closing of the acquisition of seleon GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/seleon-gmbh-becomes-part-aesco-solutions-group
Press release - 16/05/2024 Colorectal cancer: tracking down subtypes Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner. https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-tracking-down-subtypes
Press release - 15/05/2024 Tumour tissue on a chip: new possibilities for cell therapies and personalized medicine How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumour-tissue-chip-new-possibilities-cell-therapies-and-personalized-medicine
App for tuberculosis diagnosis - 15/05/2024 "Find-TB" aims to improve access to tuberculosis diagnostics Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.https://www.gesundheitsindustrie-bw.de/en/article/news/find-tb-aims-improve-access-tuberculosis-diagnostics
Press release - 13/05/2024 Detecting respiratory infections: simply blow for diagnosis Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis
Press release - 07/05/2024 Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
Press release - 06/05/2024 Research under high pressure Why 3,000 bars are needed to take a comprehensive look at a protein: Konstanz researchers Frederic Berner and Michael Kovermann present a new high-pressure spectroscopy method to unravel the properties of proteins' native structures.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-under-high-pressure
Press release - 03/05/2024 Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
Press release - 25/04/2024 Diamond dust shines bright in Magnetic Resonance Imaging An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI? https://www.gesundheitsindustrie-bw.de/en/article/press-release/diamond-dust-shines-bright-magnetic-resonance-imaging
Press release - 24/04/2024 CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
Press release - 24/04/2024 Strengthening the healthcare sector in the state: BIOPRO Baden-Württemberg networks itself strategically at a European level BIOPRO has been supporting Baden-Württemberg as a healthcare location for many years and provides important incentives for its further development. The state company has been a member of the Council of European Bioregions (CEBR) network since April 2024. Within the CEBR, BIOPRO aims to network with European cooperation partners in order to provide even better support for the innovative capacity of the healthcare industry in Baden-Württemberg.https://www.bio-pro.de/en/information/press-release/strengthening-healthcare-sector-state-biopro-baden-wuerttemberg-networks-itself-strategically-european-level
Event - 16/10/2024 - 17/10/2024 Diagnostics-4-Future Conference 2024 Konstanz, Germany, Conference https://www.gesundheitsindustrie-bw.de/en/event/diagnostics-4-future-conference-2024
Press release - 19/04/2024 Electrified bacteria PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform